True, and the 4C does seem to indicate R&D expenses will be less in the following quarter, but I really don't like the timing risk caused by cutting it so close.
Also, and strictly IMO, in past interviews James has said Recce is well funded with no need to raise capital any time soon, only to announce a raise shortly thereafter. Which, unfortunately, has caused me to question his capabilities and, sadly, honesty too.
I am happy to support their capital needs, but would much prefer James was straight with us.
If the trials are conducted well and prove successful, and the data shows Recce anti-infectives are as efficacious as earlier data indicates, then clearly this will be a game changing treatment for option many.
RCE Price at posting:
46.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)